The Market Reports

Synopsis

The global market for Therapeutic Nuclear Medicines was estimated to be worth US$ 3854 million in 2024 and is forecast to a readjusted size of US$ 7460 million by 2031 with a CAGR of 10.4% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Therapeutic Nuclear Medicines cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Therapeutic nuclear medicines are a class of pharmaceuticals that utilize radioactive isotopes to deliver cytotoxic radiation directly to diseased tissues, particularly tumors. These agents combine radioisotopes with targeting molecules—such as peptides, antibodies, or small ligands—to emit alpha, beta, or Auger electrons with high precision. This targeted radiation induces cell death while minimizing damage to surrounding healthy tissues.

Therapeutic radiopharmaceuticals are especially promising for cancers that are inoperable or unresponsive to conventional therapies, such as prostate cancer and neuroendocrine tumors. With the rapid advances in precision medicine and molecular imaging, this category is emerging as a pivotal frontier in personalized oncology, offering both clinical efficacy and strong commercial potential.

Driven by the advancement of precision medicine, therapeutic nuclear medicines are gaining momentum as a cornerstone of theranostics. Collaborations between major pharmaceutical companies and radioisotope suppliers are accelerating the development of novel radioligands, while regulatory approvals of breakthrough products are expanding the treatment landscape and attracting investor interest. Government policies supporting isotope production, nuclear logistics, and expedited approvals are further unlocking industry potential and enabling faster translation from R&D to clinical practice.

Despite their clinical promise, therapeutic radiopharmaceuticals face considerable industrial barriers. Radioisotope sourcing is restricted due to national strategic controls, and the supply chain is tightly regulated. Manufacturing and distribution require strict compliance with radiation safety, GMP standards, and cold-chain logistics, resulting in high operational thresholds. Additionally, limited awareness among physicians and patients leads to longer adoption cycles, making education and commercialization efforts critical for new entrants.

As oncology moves toward molecular subtyping and individualized treatment, demand is rising for therapies that offer high efficacy with minimal side effects. Therapeutic nuclear medicines are increasingly incorporated into treatment protocols for advanced-stage cancers. The integration of radiotherapy and diagnostics within hospital platforms is enhancing institutional acceptance and adoption. Meanwhile, global pharmaceutical leaders are accelerating the development of next-generation radiopharmaceuticals across multiple indications, driving broader clinical penetration and application scenarios.

This report aims to provide a comprehensive presentation of the global market for Therapeutic Nuclear Medicines, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Therapeutic Nuclear Medicines by region & country, by Type, and by Application.

The Therapeutic Nuclear Medicines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Therapeutic Nuclear Medicines.

Market Segmentation

By Company

• Cardinal Health
• GE Healthcare
• Lantheus Medical Imaging
• Bayer
• Eli Lilly
• Bracco Imaging
• Curium Pharma
• Jubilant Pharmova
• Aurobindo Pharma
• Novartis
• Siemens
• NTP Radioisotopes
• ANSTO
• Polatom
• China Isotope & Radiation
• Dongcheng Pharma
• Saide Bio

Segment by Type

• Radium-223
• Lutetium-177
• Iodine-131
• Other

Segment by Application

• Thyroid
• Bone Metastasis
• Lymphoma
• Other

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.